Post-marketing Study of Linagliptin: A Pilot Study [PDF]
Frontiers in Pharmacology, 2019 IntroductionLinagliptin is a high-cost oral antidiabetic that has been widely used, and studies on its effectiveness and safety for the treatment of type 2 diabetes mellitus (DM2) in the real world is rare and necessary.ObjectiveTo analyze the values of ...
Gabrielle Kéfrem Alves Gomes +3 more
doaj +5 more sources
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT) [PDF]
Journal of Diabetes Investigation, 2020 Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes
Kazunori Utsunomiya +9 more
doaj +2 more sources
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study [PDF]
Arthritis Research & Therapy, 2019 Background For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment.
Amayelle Rey +6 more
doaj +2 more sources
Post marketing study of hemodynamic and hematological noninvasive readings in a blood bank [PDF]
SAGE Open Medicine, 2018 Objectives: This validation test was conducted in the Fujisan Blood Bank, Fortaleza, Brazil and evaluated the noninvasive TensorTip MTX (MTX, Cnoga Medical Ltd.) readings of hemoglobin, hematocrit, red blood cells, blood pressure, and heart rate compared
Yosef (Joseph) Segman, Ella Sheiman
doaj +2 more sources
Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China [PDF]
Human Vaccines & ImmunotherapeuticsThis study evaluates the post-marketing safety profile of a Haemophilus influenzae Type b (Hib) conjugate vaccine in children aged 3 months to 5 y in China.
Yuxuan Zhou +5 more
doaj +2 more sources
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
The Journal of Headache and PainPurpose This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings. Methods Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 ...
Jia-Ling Hu +5 more
doaj +3 more sources
A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime
Therapeutic Advances in Drug SafetyBackground: Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear.
Cheng Jiang +4 more
doaj +3 more sources
Economica, 2023 The purpose of this study is to examine the effect of E-marketing and social media marketing toward consumer purchase decisions during the post Covid-19 pandemic with E-WOM as the mediating variable.
Eliza - Eliza +3 more
doaj +1 more source
Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study [PDF]
Pediatrics International, 2022 AbstractBackgroundThe aim of this study was to assess the long‐term safety and efficacy of sapropterin in a real‐world setting in Japanese patients with tetrahydrobiopterin (BH4)‐responsive phenylketonuria.MethodsThis post‐marketing surveillance study enrolled all of the patients in Japan with confirmed BH4‐responsive PKU who were administrated ...
Mina Tamura +4 more
openaire +2 more sources
Effectiveness of common antidepressants: a post market release study [PDF]
eClinicalMedicine, 2021 This study summarizes the experiences of patients, who have multiple comorbidities, with 15 mono-treated antidepressants.This is a retrospective, observational, matched case control study. The cohort was organized using claims data available through OptumLabs for depressed patients treated with antidepressants between January 1, 2001 and December 31 ...
Farrokh Alemi +6 more
openaire +2 more sources